Lianbo Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Lianbo Li has a total of 171 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth D. Westover
Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
16 shared publications - Nathanael Schiander Gray
Stanford University
5 shared publications Sudershan Gondi
Department of Biochemistry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA; Department of Radiation Oncology, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, USA
5 shared publications- Alberto Bremauntz Enriquez
University of Texas Southwestern Medical Center 1 Division of Endocrinology, Department of Internal Medicine Dallas, Texas
4 shared publications - Altair L. Dube
University of Texas Southwestern Medical Center 3 Cecil H. and Ida Green Center for Reproductive Biology Sciences Dallas, Texas
4 shared publications - Bruce A. Posner
University of Texas Southwestern Medical Center 2 Department of Biochemistry Dallas, Texas
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Figures S1-S6 and their legends.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Figures S1-S6 and their legends.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S9 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
S1 Differentially-expressed genes at 6-, 12-, or 24- hours (log2 >/= 1 at any time point) following EF depletion in A673 EF-SMASh cells treated with 312nM danoprevir. S2 HTS Primary Screen S3 HTS Validation Screen S4 HTS resupplied Compounds S5 Differentially expressed genes (log2 >0.58) after treatment with SW393109 or CCT251921; log2 >/= 1 for the comparator EF-depletion RNA sequencing S6 Enrichr analysis of the DEGs (log2 > 0.58) for the stated cell lines and conditions. S7 Pooled CRISPR Screening Gene-based log2 fold changes with depletion score S8 Log2 fold change in gene expression in AID-CDK8; CDK19 KO clones with 5-Ph-IAA, SW393109 or combination S9 IP-MS Proteomics Enrichment.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S9 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
S1 Differentially-expressed genes at 6-, 12-, or 24- hours (log2 >/= 1 at any time point) following EF depletion in A673 EF-SMASh cells treated with 312nM danoprevir. S2 HTS Primary Screen S3 HTS Validation Screen S4 HTS resupplied Compounds S5 Differentially expressed genes (log2 >0.58) after treatment with SW393109 or CCT251921; log2 >/= 1 for the comparator EF-depletion RNA sequencing S6 Enrichr analysis of the DEGs (log2 > 0.58) for the stated cell lines and conditions. S7 Pooled CRISPR Screening Gene-based log2 fold changes with depletion score S8 Log2 fold change in gene expression in AID-CDK8; CDK19 KO clones with 5-Ph-IAA, SW393109 or combination S9 IP-MS Proteomics Enrichment.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2366-2391
CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Ewing sarcoma is characterized by a chromosomal translocation resulting in the fusion protein EWSR1::FLI1. We utilize endogenous EWSR1::FLI1 target gene reporters in patient-derived cell lines to perform a high-throughput phenotypic screen to identify small molecules that impair the EWSR1::FLI1 transcriptional program. We discovered that inhibitors of cyclin-dependent kinase 8 (CDK8), including a novel pyridyl imidazole, altered transcription of EWSR1::FLI1 target genes and CDK8 co-localized with EWSR1::FLI1 preferentially on single GGAA DNA-binding motifs. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors suppressed proliferation of Ewing sarcoma cells through a gain-of-function mechanism by inducing molecular trapping of the CDK8 kinase module and Mediator complex on chromatin. This mechanism has implications for the development of small molecules to target transcription and suggests that impairment of transcriptional regulatory complex dynamics might serve as a vulnerability in cancers in which the dominant oncogenes act as dosage-sensitive transcription factors. Significance: A high-throughput screen using endogenous EF target gene reporter alleles identified CDK8 as a modifier of EF transcriptional regulation. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors impaired transcriptional regulation through molecular trapping of CDK8 and the Mediator complex on chromatin. See related commentary by Stevens and Hatley, p. 2210
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2366-2391
CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Ewing sarcoma is characterized by a chromosomal translocation resulting in the fusion protein EWSR1::FLI1. We utilize endogenous EWSR1::FLI1 target gene reporters in patient-derived cell lines to perform a high-throughput phenotypic screen to identify small molecules that impair the EWSR1::FLI1 transcriptional program. We discovered that inhibitors of cyclin-dependent kinase 8 (CDK8), including a novel pyridyl imidazole, altered transcription of EWSR1::FLI1 target genes and CDK8 co-localized with EWSR1::FLI1 preferentially on single GGAA DNA-binding motifs. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors suppressed proliferation of Ewing sarcoma cells through a gain-of-function mechanism by inducing molecular trapping of the CDK8 kinase module and Mediator complex on chromatin. This mechanism has implications for the development of small molecules to target transcription and suggests that impairment of transcriptional regulatory complex dynamics might serve as a vulnerability in cancers in which the dominant oncogenes act as dosage-sensitive transcription factors. Significance: A high-throughput screen using endogenous EF target gene reporter alleles identified CDK8 as a modifier of EF transcriptional regulation. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors impaired transcriptional regulation through molecular trapping of CDK8 and the Mediator complex on chromatin. See related commentary by Stevens and Hatley, p. 2210
- Open Access
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 971477
Editorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy
Editorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy
- 16 August 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 971477
Open AccessEditorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy
Editorial: Drug resistance in lung cancer chemotherapy and personalized chemotherapy
- Open Access
- 26 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7095
Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability
Thermal unfolding methods are commonly used as a predictive technique by tracking the protein’s physical properties. Inherent protein thermal stability and unfolding profiles of biotherapeutics can help to screen or study potential drugs and to find stabilizing or destabilizing conditions. Differential scanning calorimetry (DSC) is a ‘Gold Standard’ for thermal stability assays (TSA), but there are also a multitude of other methodologies, such as differential scanning fluorimetry (DSF). The use of an external probe increases the assay throughput, making it more suitable for screening studies, but the current methodologies suffer from relatively low sensitivity. While DSF is an effective tool for screening, interpretation and comparison of the results is often complicated. To overcome these challenges, we compared three thermal stability probes in small GTPase stability studies: SYPRO Orange, 8-anilino-1-naphthalenesulfonic acid (ANS), and the Protein-Probe. We studied mainly KRAS, as a proof of principle to obtain biochemical knowledge through TSA profiles. We showed that the Protein-Probe can work at lower concentration than the other dyes, and its sensitivity enables effective studies with non-covalent and covalent drugs at the nanomolar level. Using examples, we describe the parameters, which must be taken into account when characterizing the effect of drug candidates, of both small molecules and Designed Ankyrin Repeat Proteins.
- 26 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (13) , 7095
Open AccessThermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability
Thermal unfolding methods are commonly used as a predictive technique by tracking the protein’s physical properties. Inherent protein thermal stability and unfolding profiles of biotherapeutics can help to screen or study potential drugs and to find stabilizing or destabilizing conditions. Differential scanning calorimetry (DSC) is a ‘Gold Standard’ for thermal stability assays (TSA), but there are also a multitude of other methodologies, such as differential scanning fluorimetry (DSF). The use of an external probe increases the assay throughput, making it more suitable for screening studies, but the current methodologies suffer from relatively low sensitivity. While DSF is an effective tool for screening, interpretation and comparison of the results is often complicated. To overcome these challenges, we compared three thermal stability probes in small GTPase stability studies: SYPRO Orange, 8-anilino-1-naphthalenesulfonic acid (ANS), and the Protein-Probe. We studied mainly KRAS, as a proof of principle to obtain biochemical knowledge through TSA profiles. We showed that the Protein-Probe can work at lower concentration than the other dyes, and its sensitivity enables effective studies with non-covalent and covalent drugs at the nanomolar level. Using examples, we describe the parameters, which must be taken into account when characterizing the effect of drug candidates, of both small molecules and Designed Ankyrin Repeat Proteins.
- Open Access
- 1 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
ADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS–ERK–AP-1 T cell signaling-transcriptional axis
Immune stimulation fuels cell signaling-transcriptional programs inducing biological responses to eliminate virus-infected cells. Yet, retroviruses that integrate into host cell chromatin, such as HIV-1, co-opt these programs to switch between latent and reactivated states; however, the regulatory mechanisms are still unfolding. Here, we implemented a functional screen leveraging HIV-1’s dependence on CD4+ T cell signaling-transcriptional programs and discovered ADAP1 is an undescribed modulator of HIV-1 proviral fate. Specifically, we report ADAP1 (ArfGAP with dual PH domain-containing protein 1), a previously thought neuronal-restricted factor, is an amplifier of select T cell signaling programs. Using complementary biochemical and cellular assays, we demonstrate ADAP1 inducibly interacts with the immune signalosome to directly stimulate KRAS GTPase activity thereby augmenting T cell signaling through targeted activation of the ERK–AP-1 axis. Single cell transcriptomics analysis revealed loss of ADAP1 function blunts gene programs upon T cell stimulation consequently dampening latent HIV-1 reactivation. Our combined experimental approach defines ADAP1 as an unexpected tuner of T cell programs facilitating HIV-1 latency escape.
- 1 March 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-17
Open AccessADAP1 promotes latent HIV-1 reactivation by selectively tuning KRAS–ERK–AP-1 T cell signaling-transcriptional axis
Immune stimulation fuels cell signaling-transcriptional programs inducing biological responses to eliminate virus-infected cells. Yet, retroviruses that integrate into host cell chromatin, such as HIV-1, co-opt these programs to switch between latent and reactivated states; however, the regulatory mechanisms are still unfolding. Here, we implemented a functional screen leveraging HIV-1’s dependence on CD4+ T cell signaling-transcriptional programs and discovered ADAP1 is an undescribed modulator of HIV-1 proviral fate. Specifically, we report ADAP1 (ArfGAP with dual PH domain-containing protein 1), a previously thought neuronal-restricted factor, is an amplifier of select T cell signaling programs. Using complementary biochemical and cellular assays, we demonstrate ADAP1 inducibly interacts with the immune signalosome to directly stimulate KRAS GTPase activity thereby augmenting T cell signaling through targeted activation of the ERK–AP-1 axis. Single cell transcriptomics analysis revealed loss of ADAP1 function blunts gene programs upon T cell stimulation consequently dampening latent HIV-1 reactivation. Our combined experimental approach defines ADAP1 as an unexpected tuner of T cell programs facilitating HIV-1 latency escape.
- 8 October 2021
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 28 (10) , 847-857
A structural model of a Ras–Raf signalosome
The protein K-Ras functions as a molecular switch in signaling pathways regulating cell growth. In the human mitogen-activated protein kinase (MAPK) pathway, which is implicated in many cancers, multiple K-Ras proteins are thought to assemble at the cell membrane with Ras effector proteins from the Raf family. Here we propose an atomistic structural model for such an assembly. Our starting point was an asymmetric guanosine triphosphate-mediated K-Ras dimer model, which we generated using unbiased molecular dynamics simulations and verified with mutagenesis experiments. Adding further K-Ras monomers in a head-to-tail fashion led to a compact helical assembly, a model we validated using electron microscopy and cell-based experiments. This assembly stabilizes K-Ras in its active state and presents composite interfaces to facilitate Raf binding. Guided by existing experimental data, we then positioned C-Raf, the downstream kinase MEK1 and accessory proteins (Galectin-3 and 14-3-3σ) on and around the helical assembly. The resulting Ras–Raf signalosome model offers an explanation for a large body of data on MAPK signaling.
- 8 October 2021
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 28 (10) , 847-857
A structural model of a Ras–Raf signalosome
The protein K-Ras functions as a molecular switch in signaling pathways regulating cell growth. In the human mitogen-activated protein kinase (MAPK) pathway, which is implicated in many cancers, multiple K-Ras proteins are thought to assemble at the cell membrane with Ras effector proteins from the Raf family. Here we propose an atomistic structural model for such an assembly. Our starting point was an asymmetric guanosine triphosphate-mediated K-Ras dimer model, which we generated using unbiased molecular dynamics simulations and verified with mutagenesis experiments. Adding further K-Ras monomers in a head-to-tail fashion led to a compact helical assembly, a model we validated using electron microscopy and cell-based experiments. This assembly stabilizes K-Ras in its active state and presents composite interfaces to facilitate Raf binding. Guided by existing experimental data, we then positioned C-Raf, the downstream kinase MEK1 and accessory proteins (Galectin-3 and 14-3-3σ) on and around the helical assembly. The resulting Ras–Raf signalosome model offers an explanation for a large body of data on MAPK signaling.
- 1 October 2020
- Published by Elsevier in Cell Chemical Biology
- Vol. 27 (10) , 1229-1240.e4
Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing
- 1 October 2020
- Published by Elsevier in Cell Chemical Biology
- Vol. 27 (10) , 1229-1240.e4
Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing
- Open Access
- 1 September 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (17) , 3719-3731
KRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer
Assembly of RAS molecules into complexes at the cell membrane is critical for RAS signaling. We previously showed that oncogenic KRAS codon 61 mutations increase its affinity for RAF, raising the possibility that KRASQ61H, the most common KRAS mutation at codon 61, upregulates RAS signaling through mechanisms at the level of RAS assemblies. We show here that KRASQ61H exhibits preferential binding to RAF relative to PI3K in cells, leading to enhanced MAPK signaling in in vitro models and human NSCLC tumors. X-ray crystallography of KRASQ61H:GTP revealed that a hyperdynamic switch 2 allows for a more stable interaction with switch 1, suggesting that enhanced RAF activity arises from a combination of absent intrinsic GTP hydrolysis activity and increased affinity for RAF. Disruption of KRASQ61H assemblies by the RAS oligomer–disrupting D154Q mutation impaired RAF dimerization and altered MAPK signaling but had little effect on PI3K signaling. However, KRASQ61H oligomers but not KRASG12D oligomers were disrupted by RAF mutations that disrupt RAF–RAF interactions. KRASQ61H cells show enhanced sensitivity to RAF and MEK inhibitors individually, whereas combined treatment elicited synergistic growth inhibition. Furthermore, KRASQ61H tumors in mice exhibited high vulnerability to MEK inhibitor, consistent with cooperativity between KRASQ61H and RAF oligomerization and dependence on MAPK signaling. These findings support the notion that KRASQ61H and functionally similar mutations may serve as predictive biomarkers for targeted therapies against the MAPK pathway. Significance: These findings show that oncogenic KRASQ61H forms a cooperative RAS–RAF ternary complex, which renders RAS-driven tumors vulnerable to MEKi and RAFi, thus establishing a framework for evaluating RAS biomarker-driven targeted therapies.
- 1 September 2020
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (17) , 3719-3731
Open AccessKRASQ61H Preferentially Signals through MAPK in a RAF Dimer-Dependent Manner in Non–Small Cell Lung Cancer
Assembly of RAS molecules into complexes at the cell membrane is critical for RAS signaling. We previously showed that oncogenic KRAS codon 61 mutations increase its affinity for RAF, raising the possibility that KRASQ61H, the most common KRAS mutation at codon 61, upregulates RAS signaling through mechanisms at the level of RAS assemblies. We show here that KRASQ61H exhibits preferential binding to RAF relative to PI3K in cells, leading to enhanced MAPK signaling in in vitro models and human NSCLC tumors. X-ray crystallography of KRASQ61H:GTP revealed that a hyperdynamic switch 2 allows for a more stable interaction with switch 1, suggesting that enhanced RAF activity arises from a combination of absent intrinsic GTP hydrolysis activity and increased affinity for RAF. Disruption of KRASQ61H assemblies by the RAS oligomer–disrupting D154Q mutation impaired RAF dimerization and altered MAPK signaling but had little effect on PI3K signaling. However, KRASQ61H oligomers but not KRASG12D oligomers were disrupted by RAF mutations that disrupt RAF–RAF interactions. KRASQ61H cells show enhanced sensitivity to RAF and MEK inhibitors individually, whereas combined treatment elicited synergistic growth inhibition. Furthermore, KRASQ61H tumors in mice exhibited high vulnerability to MEK inhibitor, consistent with cooperativity between KRASQ61H and RAF oligomerization and dependence on MAPK signaling. These findings support the notion that KRASQ61H and functionally similar mutations may serve as predictive biomarkers for targeted therapies against the MAPK pathway. Significance: These findings show that oncogenic KRASQ61H forms a cooperative RAS–RAF ternary complex, which renders RAS-driven tumors vulnerable to MEKi and RAFi, thus establishing a framework for evaluating RAS biomarker-driven targeted therapies.